Recorded fact · drug.label_indication
drug.label_indication for mepolizumab|chronic-obstructive-pulmonary-disease
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 6823c591 resolves to.
The record
| Fact id | 6823c591508be8cbd4a2936f |
|---|---|
| Entity | drug: mepolizumab|chronic-obstructive-pulmonary-disease |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20250806 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 964d6069d369fe581f263d9016cb5d8c4f123629d587147920cd1e2823a414aa.
The value
{
"ingredient": "Mepolizumab",
"conditionId": "chronic-obstructive-pulmonary-disease",
"conditionName": "Chronic obstructive pulmonary disease",
"matchedAlias": "chronic obstructive pulmonary disease",
"context": "indication",
"brand": "Nucala",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "fefb887c-e4ac-431e-8893-e9d1a5a63fea",
"labelEffectiveTime": "20250806",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: dba3fbdefe5802c21adfec0943bf63bd1573ef63d80aee436d34356888b9c99c.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.